BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q4 2025 Earnings Call Transcript
Operator: We will be going live in five, four, three. Good afternoon. I will be your conference operator today. All lines have been placed on mute to prevent any background noise.
Bridgebio Pharma Inc. (BBIO)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Viking Global Andreas Halvorsen | 14,393,934 | $1,100,992,012 | -10% | 2.92% |
| 2. | Farallon Capital Thomas Steyer | 8,998,463 | $688,292,435 | +10% | 3.25% |
| 3. | D E Shaw D. E. Shaw | 2,214,031 | $169,351,231 | -2% | 0.09% |
| 4. | Driehaus Capital Richard Driehaus | 1,680,972 | $128,577,548 | +2% | 0.87% |
| 5. | Laurion Capital Management Benjamin A. Smith | 1,402,150 | $107,250,453 | -21% | 3.99% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.24 | 1,752 | $24,948.48 | 3,294 | 2021-12-29 | Filing | |
| $13.16 | 796 | $10,475.36 | 2,687 | 2021-12-28 | Filing | |
| $12.68 | 1,542 | $19,552.56 | 1,542 | 2021-12-28 | Filing | |
| $12.68 | 1,542 | $19,552.56 | 3,433 | 2021-12-28 | Filing | |
| $13.18 | 1,891 | $24,923.38 | 1,891 | 2021-12-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $72.80 | 602 | $43,826.20 | 234,451 | 2026-02-19 | Filing | |
| $72.08 | 8,528 | $614,701.65 | 235,053 | 2026-02-19 | Filing | |
| $71.03 | 18,923 | $1,344,189.63 | 243,581 | 2026-02-19 | Filing | |
| $74.31 | 510 | $37,898.10 | 123,945 | 2026-02-17 | Filing | |
| $75.38 | 200 | $15,076.00 | 336,585 | 2026-02-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,862,691 | $1,289,827,235 | 0.02% | |
| 2. | 14,549,529 | $1,112,893,458 | 0.02% | |
| 3. | 13,260,971 | $1,014,331,672 | 16.22% | |
| 4. | 11,000,457 | $841,348,639 | 0.38% | |
| 5. | AmundiBOND | 2,300,000 | $433,780,000 | 0.12% |
News See All
BoFA Notes BridgeBio Pharma, Inc. (BBIO)'s Upcoming Q4 Earnings May Have Limited Market Impact
TheFly reported on February 3 that Bank of America analyst Jason Zemansky raised its price target on BBIO to $88 from $85 and maintained a Buy rating on the shares.
15 Innovative Healthcare Stocks to Buy According to Analysts
Over the last two years, artificial intelligence has propelled global financial markets into a boom, with stocks reaching all-time highs.
BridgeBio (BBIO) Tumbles 15%, Mirrors Marked Bleed
Based on its historical earnings reporting dates, BridgeBio Pharma Inc.
13 Best Russell 2000 Stocks to Buy Right Now
On January 6, Royce Investment Partners released their outlook for the small-cap stocks in 2026.
Analysts Remain Positive on BridgeBio Pharma, Inc. (BBIO) After Strong 2025 Results
TheFly reported on January 8 that Truist raised its price target on BBIO to $86 from $80 while maintaining a Buy rating.
Top 10 Oncology Stocks to Buy Now
The oncology market in the United States was estimated at $81.34 billion in 2025 and is expected to reach $211.78 billion by 2034 with a compound annual growth rate of 11.75%.
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q3 2025 Earnings Call Transcript
Operator: Good afternoon. I will be your conference operator today.
BridgeBio Pharma (BBIO) Soars to All-Time High on Stellar Drug Trial Result
BridgeBio rallied for a third straight day on Monday to hit a new all-time high as investors snapped up shares following the stellar results of its final clinical trial for the study of BBP-418 in patients...
UBS Reaffirms Buy on BridgeBio (BBIO) With Optimism Around Attruby Launch
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks among the best biotech stocks to buy. UBS reaffirmed its Buy rating for BridgeBio Pharma, Inc.